Sei Investments Co. Lowers Stock Holdings in Ardent Health, Inc. $ARDT

Key Points

• Sei Investments cut its Ardent Health stake by 74.4% in the first quarter, selling 116,008 shares and retaining 39,976 shares valued at approximately $342,000.
• Several other institutional investors increased their positions, including Goldman Sachs, Ameriprise Financial, Goldentree Asset Management and Bridgeway Capital Management.
• Ardent Health reported quarterly EPS of $0.12, below the $0.18 consensus estimate, while revenue of $1.62 billion exceeded expectations. Analysts maintain a consensus “Hold” rating with an average price target of $13.05.

Sei Investments Co. trimmed its holdings in shares of Ardent Health, Inc. (NYSE:ARDT - Free Report) by 74.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 39,976 shares of the company's stock after selling 116,008 shares during the period. Sei Investments Co.'s holdings in Ardent Health were worth $342,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Goldentree Asset Management LP increased its position in Ardent Health by 99.7% during the 4th quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company's stock valued at $20,302,000 after buying an additional 1,150,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Ardent Health by 1,684.9% in the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company's stock worth $10,558,000 after acquiring an additional 724,841 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Ardent Health by 75.6% in the second quarter. Ameriprise Financial Inc. now owns 1,634,822 shares of the company's stock worth $22,332,000 after acquiring an additional 703,739 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Ardent Health by 108.2% in the fourth quarter. Bridgeway Capital Management LLC now owns 946,571 shares of the company's stock worth $8,358,000 after acquiring an additional 491,961 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Ardent Health in the third quarter worth $6,377,000.

Ardent Health Price Performance

NYSE ARDT opened at $10.93 on Monday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 3.13 and a beta of 0.70. Ardent Health, Inc. has a 1-year low of $7.71 and a 1-year high of $15.48. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.10 and a quick ratio of 1.99. The business's fifty day moving average price is $10.21 and its 200-day moving average price is $9.59.

Ardent Health (NYSE:ARDT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.06). The firm had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.59 billion. Ardent Health had a return on equity of 10.35% and a net margin of 1.22%.Ardent Health has set its FY 2026 guidance at 0.780-1.150 EPS. On average, equities analysts predict that Ardent Health, Inc. will post 0.95 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ARDT shares. UBS Group lifted their price target on Ardent Health from $13.00 to $13.50 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Guggenheim increased their price objective on shares of Ardent Health from $13.00 to $14.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Truist Financial raised their price objective on shares of Ardent Health from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $13.00 target price on shares of Ardent Health in a report on Thursday, August 6th. Finally, Weiss Ratings downgraded shares of Ardent Health from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $13.05.

Insider Activity

In other news, CFO Alfred Lumsdaine purchased 10,000 shares of the business's stock in a transaction on Friday, June 5th. The stock was acquired at an average cost of $8.81 per share, for a total transaction of $88,100.00. Following the purchase, the chief financial officer directly owned 329,183 shares in the company, valued at $2,900,102.23. This trade represents a 3.13% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.90% of the stock is currently owned by corporate insiders.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company's integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.

Want to see what other hedge funds are holding ARDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ardent Health, Inc. (NYSE:ARDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source